Status:

NOT_YET_RECRUITING

Study of Electrophysiological Markers of Antidepressants in Major Depressive Disorder

Lead Sponsor:

Centre Psychothérapique de Nancy

Conditions:

Major Depressive Disorder

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Major depressive disorder (MDD) is a frequent and particularly disabling disorder. The efficacy of current antidepressants is limited, with 50-60% of patients not achieving a sufficient response to tr...

Eligibility Criteria

Inclusion

  • Diagnosis of a current unipolar depressive episode according to DSM-V criteria
  • Prescription of antidepressant treatment - SSRI or alpha-2 antagonist - by the psychiatrist or referring physician for the current depressive episode
  • Age 18 or more
  • Affiliation with a welfare scheme and native French speakers
  • Complete information on the study received and written informed consent signed

Exclusion

  • Diagnosis of a progressive psychiatric disorder (except MDD and anxiety disorder) according to DSM-V criteria
  • Seasonal character of the depression
  • Current antidepressant treatment
  • Recommended antidepressant treatment other than SSRI or alpha-2 antagonist
  • High suicide risk
  • Retinal or ophtalmologic pathology affecting visual acuity as assessed by the Monoyer scale.
  • History of head trauma, epilepsy or other neurological disorders
  • Participation in another interventional study (including exclusion period)
  • Intellectual disability leading to difficulty participating or impossibility or inability to understand the information provided on the study.
  • Persons cited in Articles L. 1121-5 to L. 1121-8 of the French Public Health Code: pregnant women, parturient or breastfeeding mothers, persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care under duress, persons admitted to a health or social establishment for other goals than research, minors, adults subject to a legal protection, adults who are unable to express their consent and who are not subject to a legal protection measure.
  • Criteria incompatible with the use of the ERG device: open wound in an area covered or enveloped by the device; implantable medical device (e.g. pacemaker); user at high risk of contagion

Key Trial Info

Start Date :

June 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2026

Estimated Enrollment :

108 Patients enrolled

Trial Details

Trial ID

NCT06532604

Start Date

June 1 2025

End Date

July 1 2026

Last Update

May 25 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Centre Psychothérapique de Nancy

Laxou, Nancy, France, 54520